mcw casino net
2025-01-10   

mcw casino net

Developers will have to show that their project either helps reduce the amount of non-recyclable waste going to landfill, or replaces an older, less efficient incinerator. The move forms part of the Government’s drive to increase recycling rates, which have held at about 45% of household waste since 2015. Environment minister Mary Creagh said: “For far too long, the nation has seen its recycling rates stagnate and relied on burning household waste, rather than supporting communities to keep resources in use for longer. “That ends today, with clear conditions for new energy from waste plants – they must be efficient and support net zero and our economic growth mission, before they can get the backing needed to be built.” Developers will also have to ensure their incinerators are ready for carbon capture technology, and demonstrate how the heat they produce can be used to help cut heating bills for households. The Government expects that its “crackdown” on new incinerators will mean only a limited number are built, while still reducing the amount of waste sent to landfill and enabling the country to process the waste it produces. The Department for the Environment, Food and Rural Affairs said the country was almost at the point where it had enough waste facilities to handle non-recyclable rubbish, and so had limited need for new incinerators. But the proposals stop short of the plans included in the Conservatives’ 2024 manifesto, which committed to a complete ban on new incinerators due to their “impact on local communities” and declining demand as recycling increased.

CAPE CORAL, Fla. , Dec. 19, 2024 /PRNewswire/ -- Lennar, one of the nation's leading homebuilders, is proud to announce the grand opening of its newest model homes in Cape Coral, FL. The public is invited to tour stunning new model homes and discover the innovative design and quality construction that is a standard in every Lennar home. "We are pleased to introduce our newest model homes in Cape Coral , offering beautifully crafted residences without the constraints of HOA fees," said Dave Meyers , Lennar's Division Manager for Southwest Florida . "Lennar is committed to providing high-quality, move-in-ready homes that combine our signature style with the freedom and affordability that today's buyers desire. We invite prospective homeowners to explore this new community and experience the Lennar difference firsthand." The new homes in Cape Coral offer Lennar's renowned style and quality, with an emphasis on spacious layouts, contemporary finishes, and energy-efficient features—all thoughtfully included to meet the needs of today's homebuyers through the company's Everything's Included® approach. Each home is designed with functionality and comfort in mind, offering seven unique floorplans to suit different lifestyles and family sizes. Prices range from the low $300 ,000s up to $1 million for estates homes situated on the water with many options in between. Home offerings include Patio, Executive and Estate Homes with three or four bedrooms and two or three baths across 1,487 to 2,650 square feet. Situated off Burnt Store Rd South near Pine Island Rd and Matlacha , these homes are ideally located with easy access to local amenities and attractions. Cape Coral is home to over 400 miles of canals, featuring access to fresh water or the desirable Gulf Coast to offer the best of Southwest Florida living. Kayak, sail, canoe, swim, hike and trek through a truly rich ecosystem. Discover world-class dining, shopping and entertainment in this coastal city or in nearby Downtown Fort Myers . The combination of quality, affordability, and the absence of HOA fees makes these homes a compelling choice in the Cape Coral market. For more information, please visit www.lennar.com/new-homes/florida/naples-ft-myers/cape-coral/new-homes-in-cape-coral or call 239-207-3051. About Lennar Corporation Lennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations. Lennar builds affordable, move-up and active adult homes primarily under the Lennar brand name. Lennar's Financial Services segment provides mortgage financing, title and closing services primarily for buyers of Lennar's homes and, through LMF Commercial, originates mortgage loans secured primarily by commercial real estate properties throughout the United States. Lennar's Multifamily segment is a nationwide developer of high-quality multifamily rental properties. LENX drives Lennar's technology, innovation and strategic investments. For more information about Lennar, please visit www.lennar.com . Contact: Danielle Tocco Vice President Communications Lennar Corporation Danielle.Tocco@Lennar.com Direct Line: 949.789.1633 View original content to download multimedia: https://www.prnewswire.com/news-releases/lennar-debuts-new-model-homes-in-cape-coral-fl-with-no-hoa-fees-302336543.html SOURCE Lennar Corporation © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Who is Leanna Lenee, Travis Hunter's fiancee and biggest fan of the Colorado Buffaloes star?Era Of Hubristic CapitalismJoe Burrow threw three touchdown passes to Tee Higgins, including a game-winning scoring strike with 1:07 left in overtime, to give the host Cincinnati Bengals an electrifying 30-24 win over the Denver Broncos on Saturday. Cade York could have given Cincinnati (8-8) the win with 2:43 to go in the extra session, but his 33-yard field-goal attempt hit the left upright. The Bengals' defense buckled down, though, forcing Denver to go three-and-out to get Burrow, Higgins and the rest of the offense back out on the field. Cincinnati proceeded to go 63 yards in five plays, with Higgins' 3-yard TD catch giving the Bengals their fourth straight victory. Higgins finished with 11 catches for 131 yards. Marvin Mims Jr. forced overtime by hauling in a 25-yard score on fourth-and-1 to draw the Broncos (9-7) even at 24 with eight seconds left in regulation. Burrow had put Cincinnati in front by plunging into the end zone from 1 yard out just 1:21 earlier. Burrow completed 39 of 49 passes for 412 yards and the three touchdowns while Ja'Marr Chase had nine catches for 102 yards and set a single-season franchise record for receptions. He now has 117. Tight end Mike Gesicki played a key role in the Cincinnati passing game, grabbing a season-high 10 catches for 86 yards. The Bengals kept their playoff hopes alive, but they must beat the Pittsburgh Steelers in Week 18 while also getting losses from the Broncos, Miami Dolphins and Indianapolis Colts. Mims was rookie quarterback Bo Nix's favorite target, recording 103 yards and a pair of scores on eight receptions. Nix went 24-for-31 passing for 219 yards, three touchdowns and one interception. Denver is still in search of a wild-card spot and can lock one down with a win over the Kansas City Chiefs on Jan. 5. Wil Lutz booted a 30-yard field goal to open the scoring and give the Broncos a 3-0 lead. The first Burrow-to-Higgins TD -- a 2-yard connection -- put the hosts up 7-3 with 1:49 to go in the first half, and that advantage held until the break. A 22-yard field goal from York made it 10-3 with 9:07 remaining in the third quarter. Nix found Courtland Sutton for a 6-yard touchdown to tie things at 10. The teams then traded fourth-quarter TDs, with Higgins snatching a 12-yard scoring pass and Mims ending up on the receiving end of a 51-yard strike. --Field Level MediaCigna Group stock underperforms Monday when compared to competitors despite daily gains

US plans more actions against China over telecom hack

Seriki Adinoyi in Jos A non-governmental organisation, Charis Healthcare and Community Support Initiative has stated the ongoing farmer-herder crisis in Plateau State and the sit-at-home observed in South-East states have significantly impacted the mental health of women in the affected areas. Chief Executive Officer of the organization, Praise Mwuese-Ter made this assertion in Jos during a roundtable discussion to review three research findings presented by a German organisation before stakeholders. She explained that the three research reports focused on the impact of these crises on market women in particular, calling for solutions to address the challenges they face. Mwuese-Ter revealed that the women were suffering from heightened anxiety and mental health distress, stemming not only from the crises but also from the loss of loved ones during the COVID-19 pandemic. She said: “Some of the research was done in Plateau as well, and they focused on issues affecting women and society at large, including insurgency, political activities, farmer-herder clashes, and others. “We’ve found that many things have impacted women, so this roundtable is aimed at reviewing the findings of the research.” The NGO revealed that women had been severely impacted, both psychologically and economically, due to the farmer-herder crisis, COVID-19, the sit-at-home order by agitators in the South-East, and the Abuja market crisis affecting market women. “We’ve identified factors such as the socio-economic impact of these crises on women and how these events have affected their families and children, who women typically care for. We’re presenting those findings today,” Mwuese-Ter added. She also mentioned that many women experienced severe mental health distress due to heightened anxiety, which was exacerbated by the loss of loved ones. She recounted a particular case during the COVID-19 lockdown, where a woman had purchased poison to kill herself and her children due to hunger and despair. “During the COVID-19 pandemic, we received a distress call from a woman who had bought poison to kill herself and her children. They were hungry, and because of the lockdown, they could not access food. “She had been feeding the children salt water for two days and had decided to end their lives before Charis intervened,” She explained. During the roundtable, a consultant ophthalmologist and senior lecturer at Bingham University, Dr. Mercy Adejoh, discussed other challenges faced by women, including gender-based violence, economic challenges, workplace discrimination, and being relegated to the background compared to their male counterparts. She also expressed concern about the abuse of underage girls, who are often used as house helps and subjected to maltreatment, as well as the rise in rape cases leading to unwanted pregnancies. Director of the Ministry of Women Affairs in Plateau State, Sunday Donbin highlighted the state government’s efforts, including empowerment programmes and a significant increase in budgetary allocation to the Women Affairs Ministry

Exclusive-Brazil yanks temp work visas for China's BYD after trafficking claims

Carlsquare Advises Boomi on Acquisition of Data Integration Provider RiveryNYT Connections: Game #558 Hints And Answers For December 20, 2024Ria Money Transfer partners with Tenpay Global Shawn Fielder, President and CEO of Ria Money Transfer, (left) and Royal Chen, Vice President of Tencent Financial Technology, represented their companies during the signing ceremony. BUENA PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ria Money Transfer (Ria), a global leader in the cross-border money transfer industry and business segment of Euronet (NASDAQ: EEFT), and Tenpay Global, Tencent's cross-border payment platform, announced a new partnership today. Users around the world are now able to send money from Ria's digital and physical channels to their or their families' Wallet Balance or linked bank accounts in Weixin Pay, a leading payment and digital wallet in China. China remains one of the top three remittance-receiving countries globally, with remittance inflows reaching US$50 billion in 2023, according to the World Bank . This partnership enables Ria to tap into the large Weixin and WeChat user base, contributing to Ria's mobile network reach of 3.1 billion wallet accounts worldwide. With Ria's physical presence of more than 595,000 locations in nearly 200 countries and territories, Weixin Pay users in China can now receive remittances from almost anywhere across the globe and enjoy flexible spending such as transfers, top-ups and shopping. "At Ria, we are committed to harnessing technology and our powerful network to connect people and communities and help them thrive,” said Shawn Fielder, President and Chief Executive Officer of Ria Money Transfer. "Partnering with Tenpay Global combines both entities' strengths to redefine the mobile payment experience for millions of people, making it more convenient and accessible for all.” "Our partnership with Ria is founded on a shared vision of delivering cross-border remittances that bridge distances and bring families and loved ones closer together,” said Royal Chen, Vice President of Tencent Financial Technology. "Leveraging our unique Weixin ecosystem, we provide innovative cross-border solutions with convenience and reliability, meeting the evolving needs of the users and making a meaningful impact on their lives. Together with our global partners, we are creating an open, diverse and inclusive borderless payment network.” About Euronet Starting in Central Europe in 1994 and growing to a global real-time digital and cash payments network with millions of touchpoints today, Euronet now moves money in all the ways consumers and businesses depend upon. This includes money transfers, credit/debit card processing, ATMs, POS services, branded payments, foreign currency exchange and more. With products and services in more than 200 countries and territories provided through its own brand and branded business segments, Euronet and its financial technologies and networks make participation in the global economy easier, faster and more secure for everyone. A leading global financial technology solutions and payments provider, Euronet has developed an extensive global payments network that includes 55,292 installed ATMs, approximately 949,000 EFT POS terminals and a growing portfolio of outsourced debit and credit card services which are under management in 67 countries; card software solutions; a prepaid processing network of approximately 766,000 POS terminals at approximately 348,000 retailer locations in 64 countries; and a global money transfer network of approximately 595,000 locations serving 198 countries and territories. Euronet serves clients from its corporate headquarters in Leawood, Kansas, USA, and 67 worldwide offices. For more information, please visit the Company's website at www.euronetworldwide.com . About Tenpay Global Tenpay Global, the cross-border payment platform of Tencent, is the gateway to seamless cross-border payment solutions for businesses and individuals. Tenpay Global offers scenario-based services for different customer groups, including cross-border consumption, cross-border remittances, and cross-border commerce scenarios. Together with global partners, Tenpay Global is committed to bridging the world's payment networks with Weixin's ecosystem in China. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e989027-46e4-4f17-8267-411d9201ed40 CONTACT: Ria Communications Contact Maria Adriana Colella Global Communications & PR Manager [email protected]

An online debate over foreign workers in tech shows tensions in Trump's political coalition

An online debate over foreign workers in tech shows tensions in Trump's political coalition WEST PALM BEACH, Fla. Michelle L. Price, The Associated Press Dec 27, 2024 10:43 AM Dec 27, 2024 10:50 AM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Vivek Ramaswamy arrives at the Capitol in Washington, Thursday, Dec. 5, 2024, to meet with Speaker of the House Mike Johnson, R-La., and billionaire Elon Musk as they convene a meeting of the unofficial Department of Government Efficiency, or DOGE, as envisioned by President-elect Donald Trump. (AP Photo/J. Scott Applewhite) WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump's supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump's movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump's Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer , a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer's comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks , whom Trump has tapped to be the “White House A.I. & Crypto Czar." Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government , weighed in, defending the tech industry's need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump's world and what his political movement stands for. Trump has not yet weighed in on the rift, and his presidential transition team did not respond to a message seeking comment. Musk, the world's richest man who has grown remarkably close to the president-elect , was a central figure in the debate, not only for his stature in Trump's movement but his stance on the tech industry's hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry's need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent," he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Trump's own positions over the years have reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration , including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order , which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump's businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club , and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country" and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country," he told the “All-In" podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump's budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes. Michelle L. Price, The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Science News A 9th telecoms firm has been hit by a massive Chinese espionage campaign, the White House says Dec 27, 2024 10:01 AM Maryland sues maker of Gore-Tex over pollution from toxic 'forever chemicals' Dec 27, 2024 9:55 AM One owl rescued by a Minnesota woman is euthanized; efforts to save the other continue Dec 27, 2024 7:52 AMAI Fueling Duolingo's Next Growth Phase, Analyst Says

Sportscaster Greg Gumbel dies from cancer at age 78CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.With more numbers, Packard's got his party in control of policy

CHICAGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming above-ground carbon into sustainable fuels, chemicals, materials, and protein, today announced the appointment of Thierry Pilenko, former Executive Chairman of TechnipFMC plc (“TechnipFMC”), to its Board of Directors. With more than 40 years of experience in the energy and industrial sectors, Pilenko brings invaluable expertise and leadership related to large-scale infrastructure development, technology deployment, and profitable growth. Pilenko’s extensive experience and industry acumen are expected to provide valuable guidance as LanzaTech advances the commercial deployment of its technology and accelerates its timeline to profitability. “We are thrilled to welcome Thierry to our Board of Directors,” said LanzaTech Chair and CEO Dr. Jennifer Holmgren. “His proven track record of deploying innovative technologies and driving large-scale infrastructure projects will bring key insights as we execute LanzaTech’s ambitious growth strategy. Thierry spent the first 20 years of his career with Schlumberger Limited, deploying technologies on five continents. He then continued on to become a seasoned public company executive who successfully led TechnipFMC, Technip, and Veritas DGC. Throughout his exceptional career, Thierry developed a deep understanding of the global industrial landscape and the evolving competitive dynamics of the energy industry and the energy transition. Thierry’s operational leadership in global, complex and capital-intensive industries is central to advancing our mission to provide resilient, reliable technology that advances above-ground carbon recycling and produces commercial-scale ethanol that can be used in a wide range of applications, including sustainable aviation fuel.” During his tenure as Executive Chairman of TechnipFMC, and Chairman and CEO of Technip, Thierry led a large global team delivering energy solutions across 45 countries and was pivotal in overseeing Technip’s transformation and merger with FMC Technologies. This merger demonstrated the power of integration to significantly reduce costs and improve economics of large-scale projects while reducing corporate overhead costs. Under Pilenko’s leadership, Technip successfully executed landmark projects such as Shell’s $12 billion Prelude floating LNG facility and the $20+ billion Yamal LNG project. “It is an honor to join LanzaTech’s Board of Directors and contribute to the company’s pioneering and commercially proven carbon management solution,” said Pilenko. “Having spent my career in the energy sector, I understand the critical importance of deploying replicable technology solutions and know first-hand what it takes to successfully put steel in the ground and achieve desired returns. LanzaTech’s innovative approach to carbon reuse offers a unique and proven solution that will have a substantial impact on the energy transition. I am deeply committed to advancing these technologies and ensuring their widespread adoption for a more sustainable future.” In addition to joining LanzaTech’s Board, Pilenko currently serves on the boards of Arkema, a leading specialty materials company, and Trident Energy, an oil and gas production company. He is also the Board Chair of Rely, a green hydrogen-focused joint venture, and a co-founder of P6 Technologies, a SaaS platform for carbon lifecycle analysis. The appointment of Pilenko as an independent director increases LanzaTech’s board of directors to seven members, filling a previously vacant seat and further strengthening the Company’s corporate governance. About LanzaTech LanzaTech Global, Inc. (NASDAQ: LNZA) is the carbon recycling company transforming waste carbon into sustainable fuels, chemicals, materials, and protein for everyday products. Using its biorecycling technology, LanzaTech captures carbon generated by energy-intensive industries at the source, preventing it from being emitted into the air. LanzaTech then gives that captured carbon a new life as a clean replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. By partnering with companies across the global supply chain like ArcelorMittal, Coty, Craghoppers, REI, and LanzaJet, LanzaTech is paving the way for a circular carbon economy. For more information about LanzaTech, visit https://lanzatech.com . Forward Looking Statements This press release includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs, assumptions, projections and conclusions of LanzaTech’s management. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, many of which are outside LanzaTech’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. LanzaTech cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are not guarantees of future performance, conditions or results, and you should not rely on forward-looking statements. Generally, statements that are not historical facts, including those concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or similar expressions. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: timing delays in the advancement of projects to the final investment decision stage or into construction; failure by customers to adopt new technologies and platforms; fluctuations in the availability and cost of feedstocks and other process inputs; the availability and continuation of government funding and support; broader economic conditions, including inflation, interest rates, supply chain disruptions, employment conditions, and competitive pressures; unforeseen technical, regulatory, or commercial challenges in scaling proprietary technologies, business functions or operational disruptions; and other economic, business, or competitive factors, and other risks and uncertainties, including the risk factors and other information contained in LanzaTech’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, as well as other existing and future filings with the U.S. Securities and Exchange Commission. Any forward-looking statement herein is based only on information currently available to LanzaTech and speaks only as of the date on which it is made. LanzaTech undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Relations Kate Walsh VP, Investor Relations & Tax Investor.Relations@lanzatech.com Media Relations Kit McDonnell Director of Communications press@lanzatech.com

Government to block incinerators that do not contribute to green plans42 West Virginia counties begin concurrent bear, deer hunting seasons

Related hot word search:

Previous: mcw casino mx
Next: mcw casino online